论文部分内容阅读
目的 探讨CYFRA2 1 1和NSE在血清中的表达及其对原发性肺癌 (PLC)的诊断 ,病情监测及疗效判定的临床应用价值。方法 分别在手术 ,放疗或化疗前后 2周内采集PLC病人血清标本 162份。采用酶联免疫分析方法检测标本血清中CYFRA2 1 1和NSE的表达情况。结果 PLC病人血清CYFRA2 1 1和NSE水平均明显高于肺良性疾病和正常对照组 (P <0 .0 1)。非小细胞肺癌 (NSCLC)病人血清CYFRA2 1 1和NSE总体表达水平和检测阳性率分别为10 2 .3 2± 5 5 .63U /L(4 7.5 3 % )和 3 3 .3 6± 17.5 2 μg/L(4 5 .0 6% ) ,其中鳞癌 (SqC)分别为 13 4.75± 68.5 9U/L(72 .88% )和2 5 .3 6± 13 .81μg/L(3 3 .89% ) ,腺癌 (AC)分别为 98.5 8± 49.2 3U /L (4 0 .91% )和 2 2 .97± 11.65 μg/L(4 0 .91% ) ,且随TNM发展而升高。血清CYFRA2 1 1和NSE的表达水平在手术后 2周显著下降 (P <0 .0 5 )。病情稳定 ,疗效较好的患者血清CYFRA2 1 1和NSE表达无明显变化 ;病情进展、疗效较差的患者明显升高 (P <0 .0 5 )。结论 CYFRA2 1 1和NSE表达水平对PLC的诊断 ,病情监测及疗效判定均有较好的临床应用价值
Objective To investigate the expression of CYFRA2 1 1 and NSE in serum and its clinical value in the diagnosis, diagnosis and prognosis of primary lung cancer (PLC). Methods 162 serum samples from PLC patients were collected before and after surgery, radiotherapy or chemotherapy respectively. Enzyme-linked immunosorbent assay was used to detect the serum CYFRA21-1 and NSE expression. Results The levels of serum CYFRA2 1 1 and NSE in PLC patients were significantly higher than those in benign lung diseases and normal controls (P <0.01). The overall expression of CYFRA21-1 and NSE in non-small cell lung cancer (NSCLC) patients and their positive rates were 102.32 ± 5.55.63U / L (4 7.53%) and 33.6 ± 17.52 (SqC) were 13 4.75 ± 68.5 9U / L (72.88%) and 25.36 ± 13.81μg / L (3 3 .89 %) And adenocarcinoma (AC) were 98.5 8 ± 49.2 3U / L (40.91%) and 22.97 ± 11.65 μg / L (40.91%), respectively. Serum levels of CYFRA21-1 and NSE were significantly decreased 2 weeks after surgery (P <0.05). Serum levels of CYFRA21-1 and NSE in patients with stable disease and good curative effect showed no significant changes. Patients with poor prognosis and poor prognosis were significantly higher (P <0.05). Conclusion The expression levels of CYFRA2 1 1 and NSE have a good clinical value in diagnosis of PLC, monitoring of disease and determination of therapeutic effect